.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Colorcon
Healthtrust
Chinese Patent Office
Farmers Insurance
Medtronic
US Department of Justice
Fuji
Julphar
US Army

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,891,868

« Back to Dashboard

Which drugs does patent 5,891,868 protect, and when does it expire?


Patent 5,891,868 protects MENOSTAR and is included in one NDA.

This patent has thirty-seven patent family members in twenty-five countries.

Summary for Patent: 5,891,868

Title: Methods for treating postmenopausal women using ultra-low doses of estrogen
Abstract:The present invention provides methods for treating physical conditions resulting from postmenopausal estrogen decline in a postmenopausal subject, and in particular methods for reducing the risk of osteoporotic bone fractures in a postmenopausal subject. The present invention also provides a kit useful for carrying out the methods of the present invention.
Inventor(s): Cummings; Steven (Mill Valley, CA), Ellman; Herman (Mountain Lakes, NJ), Ettinger; Bruce (San Francisco, CA)
Assignee: Kaiser Foundation Health Plan, Inc. (Oakland, CA) Permanente Medical Group, Inc. (Oakland, CA) The Regents of the University of California (Oakland, CA) Berlex Laboratories (Richmond, CA)
Application Number:08/975,599
Patent Claim Types:
see list of patent claims
Use; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Bayer HlthcareMENOSTARestradiolFILM, EXTENDED RELEASE;TRANSDERMAL021674-001Jun 8, 2004RXYesYes► Subscribe► Subscribe► SubscribeYPREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 5,891,868

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,692,763 Methods for treating postmenopausal women using ultra-low doses of estrogen► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,891,868

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China1279611► Subscribe
China100398110► Subscribe
Czech Republic20001602► Subscribe
Czech Republic299226► Subscribe
Germany69829501► Subscribe
Germany69839026► Subscribe
Denmark1032398► Subscribe
Eurasian Patent Organization200000563► Subscribe
Eurasian Patent Organization004573► Subscribe
Estonia200000307► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Citi
Healthtrust
Farmers Insurance
Julphar
Daiichi Sankyo
US Army
McKinsey
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot